东阳光（600673）长江药业(01558)发布公告，该公司将于2025年10月31日派发特别股息每股1.5港元。 ...

Group 1 - The company Dongyangguang Changjiang Pharmaceutical (01558) announced a special dividend of HKD 1.5 per share to be distributed on October 31, 2025 [1]

Core Insights - Dongyangguang Group is entering a new development phase with the upcoming IPO of Dongyangguang Pharmaceutical, marking a significant step in China's innovative pharmaceutical sector [1][5] - The company has established itself as a leader in three major industries: electronic new materials, biomedicine, and health preservation, with a strong focus on innovation and internationalization [2][11] Group 1: Company Overview - Dongyangguang Group has grown from a small enterprise to a major player with over 30,000 employees and assets exceeding 80 billion RMB, achieving a cumulative tax contribution of over 23 billion RMB [2][5] - The company has successfully launched multiple globally leading products and has two listed companies, Dongyangguang and Dongyangguang Changjiang Pharmaceutical [1][2] Group 2: Industry Position and Strategy - The group is strategically positioned in the electronic new materials sector, focusing on AI and robotics, and aims to become a leader in the liquid cooling technology market within five years [3][4] - Dongyangguang Pharmaceutical has a robust pipeline with 150 approved drugs and over 100 in development, aiming to become a top-tier pharmaceutical company in China and globally [5][6] Group 3: Research and Development - The company has established a comprehensive R&D system with over 1,100 researchers, focusing on innovative drug development and maintaining a leading position in the industry [6][14] - Dongyangguang Pharmaceutical has received multiple awards for innovation and has a strong patent portfolio, ranking first among domestic pharmaceutical companies in terms of patent applications [14][15] Group 4: Market Expansion and Internationalization - The company has built a global sales network, covering eight countries, and is actively pursuing international clinical trials and licensing agreements for its innovative drugs [15][16] - Dongyangguang Pharmaceutical's insulin products are expected to capture significant market share in the U.S., with potential sales exceeding 10 billion USD [15][16] Group 5: Social Responsibility and Corporate Culture - Dongyangguang Group emphasizes social responsibility, having donated over 500 million RMB to various charitable causes and providing employment opportunities in its operational regions [16][17] - The company fosters a culture of innovation and commitment to national development, aligning its growth with the broader economic goals of China [16][17]

东阳光集团广东乳源基地 ...

地本版图片均为公司供图 东阳光集团浙江东阳基 ...

东阳光集团广东东莞总部 ...

Core Viewpoint - Dongyangguang Group is entering a new development stage with the upcoming IPO of Dongyangguang Pharmaceutical, marking a significant step in China's innovative pharmaceutical sector [1][5]. Group Overview - Established 28 years ago, Dongyangguang Group has grown from scratch to a private enterprise with over 30,000 employees and assets exceeding 80 billion yuan, becoming a leader in multiple industries including electronic new materials, biomedicine, and health care [1][2]. - The company has successfully cultivated two publicly listed companies with market capitalizations in the hundred billion range [1]. Industry Development - The group is actively expanding into the artificial intelligence and robotics sectors, recognizing the potential of AI as a new engine for high-quality development [2][3]. - Dongyangguang has established a complete fluorine and chlorine chemical industry chain, positioning itself as the only company in South China with such capabilities [4]. Pharmaceutical Sector - Dongyangguang Pharmaceutical has 150 globally approved drugs and over 100 in the pipeline, aiming to become a leading pharmaceutical enterprise in China and globally [5][6]. - The company has established a robust R&D system and has been recognized for its innovation, winning multiple awards and holding over 2,500 patents [6][11]. Health and Wellness Industry - The company has pioneered the ecological breeding of Cordyceps sinensis, achieving significant production milestones and aiming for an annual output of 100 tons with sales exceeding 10 billion yuan [7][8]. - Dongyangguang is developing a product matrix around Cordyceps, targeting the burgeoning health and wellness market [8]. Innovation and Internationalization - The group emphasizes innovation and internationalization as core strategies, having built a strong R&D platform and established a global sales network covering eight countries [9][12]. - Dongyangguang has made significant investments in R&D, including collaborations with international experts and institutions to enhance its competitive edge [11][12]. Social Responsibility - Dongyangguang Group has committed over 500 million yuan to public welfare and has created over 10,000 job opportunities, reflecting its dedication to social responsibility [14].

广东东阳光科技控股股份有限公司 关于控股股东之一致行动人部分股份质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 证券代码：600673 证券简称：东阳光 编号：临2025-49号 重要内容提示: 债券代码：242444 债券简称：25东科01 ● 控股股东之一致行动人宜昌东阳光药业股份有限公司（以下简称"宜昌药业股份"）持有本公司股份 545,023,350股，占公司总股本的18.11%；截至本次股份质押完成后，宜昌药业股份持有本公司股份累 计质押数量531,500,000股，占其持股数量的97.52%。 截至本公告披露日，深圳东阳光实业及其一致行动人累计质押股份情况如下： ■ 三、上市公司控股股东股份质押情况 1、控股股东深圳东阳光实业未来半年内将到期的质押股份数量累计8,678.94万股，占其所持股份的 14.05%，占公司总股本的2.88%，对应融资余额102,499.70万元；一年内将到期的质押股份数量累计 28,258.94万股，占其所持股份的45.75%，占公司总股本的9.39%，对应融资余额505,0 ...

| 证券代码：600673 | 证券简称：东阳光 | | 编号：临 | 2025-49 号 | | --- | --- | --- | --- | --- | | 债券代码：242444 | 债券简称：25 东科 | 01 | | | 截至本公告披露日，公司控股股东累计质押股数数量为 551,798,054 股， 占其持股数量的 89.34%；控股股东及其一致行动人累计质押股数数量为 1,264,388,597 股，占合计持股数量比例为 79.62%。 一、本次股份质押基本情况 广东东阳光科技控股股份有限公司（以下简称"公司"）于近日收到控股股 东之一致行动人宜昌药业股份的通知，获悉其将其持有的公司部分无限售流通股 进行了质押，具体事项如下： | 股东名称 | 是否 为控 | 本次质押股数 | 是否 | 是否 | | | | | 占其所 | 占公司 | 质押 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 为限 | 补充 | 质押起始日 | | 质押到期日 | 质权人 | 持股份 | 总股本 ...

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 从资金流向上来看，当日综合板块主力资金净流出1.14亿元，游资资金净流入4390.61万元，散户资金净 流入6996.74万元。综合板块个股资金流向见下表： 证券之星消息，7月30日综合板块较上一交易日下跌1.08%，东阳光领跌。当日上证指数报收于 3615.72，上涨0.17%。深证成指报收于11203.03，下跌0.77%。综合板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 600689 | 上海三毛 | 12.58 | 1.53% | 4.87万 | 6053.67万 | | 000523 | 红棉股份 | 3.36 | 1.20% | 28.99万 | 9701.31万 | | 000652 | 泰达股份 | 4.51 | 0.89% | 26.46万 | 1.19亿 | | 000753 | 漳州发展 | 5.69 | 0.89% | 37. ...